|
30 Mar 2007 |
Arpida announces promising results of "first-in-man" studies with AR-709
|
|
30 Mar 2007 |
Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha Antagonist
|
|
30 Mar 2007 |
Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I Clinical Trial with Next-Generation Drug Candidate HE3286 in Metabolic Disorders
|
|
29 Mar 2007 |
Anesiva Commences Phase 3 Clinical Study of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
|
|
29 Mar 2007 |
Clinical Development Initiated on Lead Compound in NicOx Glaucoma Collaboration with Pfizer
|
|
29 Mar 2007 |
Merck & Co., Inc. and Lundbeck discontinue joint development program for gaboxadol, an investigational compound for insomnia
|
|
29 Mar 2007 |
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil, Its New Long Acting Drug For Erectile Dysfunction
|
|
29 Mar 2007 |
Samaritan Pharma Partners PII HIV Drug to Pharmaplaz; Upfront Payment $10 Million
|
|
29 Mar 2007 |
Portola Pharmaceuticals, Inc. Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
|
|
28 Mar 2007 |
Biocryst Pharmaceuticals (BCRX) Places Hold on Trial of IV Leukemia Drug
|
|
28 Mar 2007 |
Barrier Therapeutics, Inc. (BTRX) Announces Azoline (Pramiconazole) Dose Ranging Study in Tinea Versicolor Meets Primary and Secondary Endpoints
|
|
28 Mar 2007 |
AtheroGenics Announces ARISE Phase III Clinical Study Results at the American College of Cardiology's 56th Annual Scientific Session
|
|
28 Mar 2007 |
Horizon Therapeutics Begins Patient Enrollment in Phase 3 Trials for 'GI-Friendly' NSAID
|
|
28 Mar 2007 |
Allon receives approval to begin a Phase II clinical trial for Schizophrenia
|
|
28 Mar 2007 |
Adherex Initiates Combination Trial of ADH-1 and Melphalan for Treatment of Melanoma
|
|
28 Mar 2007 |
CuraGen and TopoTarget Initiate Phase II Trial of Belinostat (PXD101) in Combination with Velcade(R) for Refractory Multiple Myeloma
|
|
28 Mar 2007 |
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
|
|
28 Mar 2007 |
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
|
|
28 Mar 2007 |
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
|
|
27 Mar 2007 |
Semafore Pharmaceuticals Initiates Phase I Clinical Trial of PI3K Inhibitor SF1126 in Solid Tumor Cancers
|
|
27 Mar 2007 |
Schering-Plough and Merck to Develop Another New Cholesterol Lowering Medicine
|
|
27 Mar 2007 |
Tekturna(R), first new type of high blood pressure medicine in a decade, provides additional blood pressure reduction when used with Diovan(R)
|
|
27 Mar 2007 |
Indevus Reports That Interim Review of NEBIDO(R) Phase III Data Indicates Trial Is Likely to Meet Primary Endpoints
|
|
27 Mar 2007 |
DiObex announces successful completion of phase 2a trial
|
|
27 Mar 2007 |
Ocera Therapeutics Initiates a Phase 2 Trial for Active Pouchitis
|
